CARDIONOVUM, a medical technology company based in Bonn, Germany, develops and commercializes innovative medical devices such as the new generation of DCB and drug-eluting stents for the treatment of coronary and peripheral artery disease. The company’s pioneering range of DCBs is based on the SAFEPAX® paclitaxel coating matrix which has the lowest wash-off rates on the market. The company’s strong commitment to clinical research ensures a continually deepening and expanding evidence-base in support of the clinical benefits of our products. Pioneers in medical devices. The worldwide first CE-approved DCB. With the first DCB market introduction, CARDIONOVUM contributed significantly to the establishment of a new medical device therapy to treat coronary and peripheral artery disease effectively. CARDIONOVUM consists of R & D staff, with the longest and most profound experience, in developing clinically advanced DCB and DES cardiovascular devices. “Live Deserves the Best”
